Citius Oncology, Inc.
NASDAQ:CTORDrug Manufacturers - General
+$0.03 today
- Market cap
- $51.83M
- Beta
- 3.42
- P/E (TTM)
- -1.6
- EPS (TTM)
- -$0.42
Volume 0.15M
Average 0.12M
CTOR Operating Expenses
Total costs of running the business that are not directly tied to producing goods or services sold.
Citius Oncology, Inc.NASDAQ: CTOR
Operating Expenses · Q2 FY2026 · quarter ended Mar 2026
Operating expenses growth accelerates
Q2 FY2026 operating expenses of $29.95M rose 300.9% year over year, ahead of the +90.8% change in trailing-twelve-month operating expenses. Sequentially, it rose 256.3% from the prior quarter. Over 3 fiscal years it compounded at +34.3% a year.
Context
- Operating expenses increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +300.9% holds above the trailing-twelve-month pace of +90.8%.
Sources:Income StatementText generated from reported figures; not investment advice.
Operating Expenses history
USD · from the income statement
- Latest · FY2025
- 23.52M USD
- Year-over-year change
- +14.3%
- 3-year CAGR
- +34.3%
| Period | Period end | Operating Expenses | YoY change |
|---|---|---|---|
| FY2025 | 2025-09-30 | 23.52M | +14.3% |
| FY2024 | 2024-09-30 | 20.57M | +69.7% |
| FY2023 | 2023-09-30 | 12.12M | +24.8% |
| FY2022 | 2022-09-30 | 9.71M | — |
Operating Expenses vs competitors
How CTOR compares with its peers on the latest reported figures
- CTOR's LTM Mar 2026 operating expenses of $48.02M is the 7th highest of the 10 companies compared; the peer median is $76.99M.
- Its year-over-year change of +90.8% is the 4th highest of 10, against a peer median of +16.3%.
- Operating expenses amounts to 855.7% of revenue for CTOR, versus a peer median of 473.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $373.48M | +210.2% | +63.9% | — | |
| LTM Mar 2026 | $295.28M | +130.2% | +54.5% | 872.0% | |
| LTM Mar 2026 | $113.16M | -11.7% | -28.7% | 1791.7% | |
| LTM Mar 2026 | $87.4M | -16.0% | -20.4% | 7620.1% | |
| LTM Mar 2026 | $76.99M | +71.5% | +72.0% | — | |
| LTM Mar 2026 | $65.53M | +7.1% | -17.0% | 61.2% | |
CTORCitius Oncology, Inc. | LTM Mar 2026 | $48.02M | +90.8% | +34.3% | 855.7% |
| LTM Mar 2026 | $42.7M | +16.3% | +8.8% | 74.0% | |
| LTM Mar 2026 | $41.26M | +410.9% | -13.1% | 75.3% | |
ACTUActuate Therapeutics Inc | LTM Mar 2026 | $21.83M | -8.1% | +3.6% | — |
| Peer median (excluding CTOR) | $76.99M | +16.3% | +3.6% | 473.7% | |
Competitors are the stored peer set for CTOR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2022 Sep 2022 | FY2023 Sep 2023 | FY2024 Sep 2024 | FY2025 Sep 2025 |
|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — |
| Research & Development | 6.86M | 4.24M | 4.93M | 6.42M |
| Selling, General & Admin | 2.86M | 7.88M | 15.65M | 17.1M |
| Operating Expenses | 9.71M | 12.12M | 20.57M | 23.52M |
| Depreciation & Amortization | 9.71M | 0 | 0 | 0 |
| EBITDA | 0 | (12.12M) | (20.57M) | (23.49M) |
| EBITDA Margin | — | — | — | — |
| Operating Income | (9.71M) | (12.12M) | (20.57M) | (23.52M) |
| Operating Margin | — | — | — | — |
| Interest Income | 0 | 0 | 0 | 36.37K |
| Interest Expense | 0 | 0 | 0 | 218.03K |
| Other Income / Expenses | 0 | 0 | 0 | (181.66K) |
| Income Before Tax | (9.71M) | (12.12M) | (20.57M) | (23.7M) |
| Pre-Tax Margin | — | — | — | — |
| Income Tax Expense | 1.15M | 576K | 576K | 1.06M |
| Net Income | (10.87M) | (12.7M) | (21.15M) | (24.76M) |
| Net Margin | — | — | — | — |
| EPS (Basic) | (0.08) | (0.19) | (0.30) | (0.34) |
| EPS (Diluted) | (0.08) | (0.19) | (0.30) | (0.34) |
| Weighted Avg Shares | 90.16M | 89.48M | 71.55M | 73.27M |
| Weighted Avg Shares (Diluted) | 90.16M | 89.48M | 71.55M | 73.27M |
Citius Oncology, Inc.
NASDAQ:CTOR
Intrinsic Alpha fair value
Locked
Current Price
$0.56
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.